LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Strona główna・Stock List・AnaptysBio Inc

AnaptysBio Inc

Closed

SectorHealthcare

59.71 -0.99

Buy Sell

Overview

Share price change

24h

Current

Min

59.17

Max

60.13

Key metrics
By Trading Economics
Income	-102M -53M
Sales	-83M 26M
Profit margin	-206.934
Employees	104
EBITDA	-102M -34M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+36.26% upside

Dividends
By Dow Jones
Next Earnings	4 sie 2026

Market Stats
By TradingEconomics
Market Cap	-219M 1.8B
Previous open	60.7
Previous close	59.71

News Sentiment

By Acuity

50%

159 / 345 Ranking in Healthcare

AnaptysBio Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

25 maj 2026, 08:24 UTC

Major Market Movers

Acquisitions, Mergers, Takeovers

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25 maj 2026, 21:22 UTC

Earnings

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25 maj 2026, 20:50 UTC

Market Talk

Earnings

Basic Materials Roundup: Market Talk

25 maj 2026, 16:20 UTC

Market Talk

Earnings

Basic Materials Roundup: Market Talk

25 maj 2026, 16:01 UTC

Market Talk

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25 maj 2026, 14:43 UTC

Market Talk

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25 maj 2026, 14:15 UTC

Market Talk

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25 maj 2026, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25 maj 2026, 12:58 UTC

Market Talk

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25 maj 2026, 12:56 UTC

Market Talk

Earnings

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25 maj 2026, 12:48 UTC

Market Talk

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25 maj 2026, 12:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25 maj 2026, 12:34 UTC

Market Talk

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25 maj 2026, 12:10 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Delivery Hero's Assets Look Strategic -- Market Talk

25 maj 2026, 11:00 UTC

Market Talk

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25 maj 2026, 10:19 UTC

Market Talk

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25 maj 2026, 10:05 UTC

Earnings

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25 maj 2026, 10:04 UTC

Earnings

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25 maj 2026, 10:03 UTC

Earnings

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25 maj 2026, 10:02 UTC

Earnings

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25 maj 2026, 10:01 UTC

Earnings

Tenaga Nasional 1Q Net Up 3.7% on Year

25 maj 2026, 10:00 UTC

Earnings

Tenaga Nasional 1Q Rev Up 6.6% on Year

25 maj 2026, 09:56 UTC

Earnings

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25 maj 2026, 09:56 UTC

Earnings

Tenaga Nasional 1Q EPS MYR0.1883

25 maj 2026, 09:56 UTC

Earnings

Tenaga Nasional 1Q Rev MYR17.1B

25 maj 2026, 09:56 UTC

Earnings

Tenaga Nasional 1Q Net MYR1.1B

25 maj 2026, 09:38 UTC

Market Talk

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25 maj 2026, 09:33 UTC

Market Talk

Global Equities Roundup: Market Talk

25 maj 2026, 09:33 UTC

Market Talk

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25 maj 2026, 08:55 UTC

Market Talk

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Peer Comparison

Price change

AnaptysBio Inc Forecast

Price Target

By TipRanks

36.26% upside

12 Months Forecast

Average 81.36 USD 36.26%

High 140 USD

Low 50 USD

Based on 11 Wall Street analysts offering 12 month price targets forAnaptysBio Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to AnaptysBio Inc - Dist in the past 3 months.

Sentiment

By Acuity

159 / 345 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.